Skip to main content
Coloplast logo

Coloplast — Investor Relations & Filings

Ticker · COLO ISIN · DK0060448595 LEI · 529900NN7SOJ5QG82X67 CO Manufacturing
Open in API
Filings indexed 2,462 across all filing types
Latest filing 2023-07-07 M&A Activity
Country DK Denmark
Listing CO COLO

About Coloplast

https://www.coloplast.com

Coloplast is a company that develops, manufactures, and markets medical devices and services for people with intimate healthcare needs. Its principal business areas include Ostomy Care, Continence Care, Interventional Urology, and Wound & Skin Care. By collaborating closely with users, the company creates solutions designed to make life easier for individuals with personal and private medical conditions. Coloplast also provides comprehensive support programs and educational resources for both patients and healthcare professionals.

Recent filings

Filing Released Lang Actions
M&A Activity 2023
M&A Activity Classification · 1% confidence The document is an announcement by Coloplast regarding the agreement to acquire Kerecis. It details the transaction value, financing structure (equity capital raise), expected financial impacts (growth guidance adjustment), and includes details about an upcoming conference call. This type of announcement, detailing a major corporate transaction like an acquisition, falls under Capital/Financing Update (CAP) as it directly concerns capital structure changes and fundraising, or potentially Regulatory Filings (RNS) if it were a general disclosure. However, given the specific focus on financing the acquisition via an equity capital raise and the material nature of the transaction, CAP is a strong fit. Since it is a detailed announcement of a major transaction and financing, it is not a simple 'Report Publication Announcement' (RPA). The key elements are the acquisition and the planned equity capital raise to finance it.
2023-07-07 English
Coloplast A/S - Announcement no. 03/2023 - Coloplast announces agreement to acquire Kerecis and raises long-term growth expectations
M&A Activity Classification · 1% confidence The document is a corporate announcement regarding a definitive agreement to acquire Kerecis for USD 1.3 billion. It details the strategic rationale, financial impact, and financing plans (capital increase). While it contains significant M&A information, it is structured as a formal company announcement (Selskabsmeddelelse) regarding a transaction. According to the provided definitions, M&A activity announcements fall under the 'TAR' category.
2023-07-07 Danish
Coloplast A/S - Announcement no. 03/2023 - Coloplast announces agreement to acquire Kerecis and raises long-term growth expectations
M&A Activity Classification · 1% confidence The document is an official announcement from Coloplast A/S regarding a definitive agreement to acquire Kerecis for USD 1.3 billion. It details the strategic rationale, financial impact, and financing plans (equity capital raise). While it mentions a conference call, the primary purpose of the document is to announce a major M&A transaction. Therefore, it falls under the M&A Activity category.
2023-07-07 Danish
Earnings Release 2023
Earnings Release Classification · 1% confidence The document is explicitly titled 'Coloplast A/S - Announcement no. 02/2023 - Interim Financial Report, H1 2022/23'. It contains detailed financial results for the first half of the fiscal year (H1 2022/23, covering 1 October 2022 - 31 March 2023), including revenue, EBIT margin, segment performance, and updated full-year guidance. This content aligns perfectly with the definition of an Interim / Quarterly Report (IR). Although it mentions a conference call and has an attachment named 'Earnings_Release', the core content provided is the comprehensive interim financial report itself, not just a brief announcement of its publication. Therefore, the classification should be IR. H1 2023
2023-05-11 English
Earnings Release 2023
Earnings Release Classification · 1% confidence The document is titled 'Coloplast A/S - Selskabsmeddelelse nr. 02/2023 - Regnskabsmeddelelse, 1. halvår 2022/23' (Company Announcement No. 02/2023 - Financial Report, 1st half-year 2022/23). It contains detailed financial figures for the first half of the fiscal year (1. oktober 2022 – 31. marts 2023), including organic growth, revenue, EBIT, profit margin, and guidance updates. This content strongly indicates a comprehensive financial report for a period shorter than a year. This aligns perfectly with the definition of an Interim / Quarterly Report (Code: IR). Although it is presented as a 'Selskabsmeddelelse' (Company Announcement), the core content is the financial report itself, not just an announcement that a report is attached (which would suggest RPA or RNS). The length (8446 chars) is substantial enough to contain the report summary, and the presence of a teleconference announcement further supports this being the primary release of the interim results. H1 2023
2023-05-11 Danish
Coloplast A/S - Announcement no. 02/2023 - Interim Financial Report, H1 2022/23
Interim / Quarterly Report Classification · 1% confidence The document is a 'Regnskabsmeddelelse' (Financial Statement/Report) for the first half (H1) of the 2022/23 fiscal year for Coloplast. It contains detailed financial statements, including income statements, balance sheets, cash flow data, and management commentary on strategic priorities (Strive25) and sales performance. Since it provides comprehensive financial data for an interim period (6 months) and is not merely an announcement of a report, it is classified as an Interim/Quarterly Report. H1 2023
2023-05-11 Danish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.